Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224464 · ClinicalTrials.gov registry record · NA

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

A NA study of Metastatic Solid Tumors and Stage 4 Cancer, sponsored by New Phase.

Recruiting
Registry status
NA
Development phase
9
Enrollment target
1
Study location

NCT07224464 is a NA study of Metastatic Solid Tumors and Stage 4 Cancer that is actively recruiting participants, run by New Phase. The registered enrollment target is 9 participants, below the 206-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224464, a NA study of Metastatic Solid Tumors and Stage 4 Cancer, is actively recruiting participants, sponsored by New Phase.

RECRUITING
Registry status
NA
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Eligible participants have stage 4 metastatic solid tumor(s), that is(are) not responding to conventional treatment or have declined standard treatment options. The main question it aims to answer is: • What is the safety profile of the Sarah Nanotechnology System and which field strength and time of irradiation are safe for people? Study participation involves: * One intravenous injection (through a vein in the arm) of a solution that contains tiny particles (nanoparticles) containing iron oxide. The nanoparticles are delivered to the tumor(s) through blood circulation. * About 4 hours after injection of the nanoparticles, participants are placed inside a machine (magnetic field system) where the upper torso will be exposed to low frequency (\~300 kHz) alternating magnetic field (AMF) radiation. This type of radiation, unlike CT or X- rays, is non-ionizing. Non-ionizing means radiation that lacks the energy to remove electrons from an atom. Examples of devices that produce non-ionizing radiation are MRI machines, cell phones, Wi-Fi, microwave ovens, and sunlight. The AMF heats up the iron oxide core in the nanoparticles, due to their magnetic properties, which in turn causes the temperature to increase within the tumor(s). Because cancer cells are more sensitive to heat than normal cells, the heat will damage the cancer cells potentially without harming the surrounding healthy tissues. * During the treatment participants are covered by a cooling blanket to control body temperature, which will be monitored continuously throughout the procedure. * Participants are followed up at 1 week and 1 month, and up to 5 years after the one-time treatment.

Interventions

  • DEVICE The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2025-12-16
Est. Completion 2030-12
Phase NA

Sponsor

New Phase

1 total trials

What the Registry Record Tells You About NCT07224464

The ClinicalTrials.gov registry entry for NCT07224464 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (96% lower). The listed sponsor is New Phase, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors. is the first listed.

NCT07224464 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT07224464 about?

NCT07224464 is a clinical study titled "The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.". This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Eligible participants have stage 4 metastatic solid tumor(s), that is(are) ...

What is the current status of trial NCT07224464?

This trial is currently recruiting. It is a NA study. The enrollment target is 9 participants. The study started on 2025-12-16. Estimated completion is 2030-12.

What conditions does trial NCT07224464 study?

This clinical trial studies the following conditions: Metastatic Solid Tumors, Stage 4 Cancer.

What interventions are being tested in trial NCT07224464?

The interventions under investigation include: The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors. (DEVICE).

Who is sponsoring clinical trial NCT07224464?

This trial is sponsored by New Phase, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07224464 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.